Of course I came to the above link and also to CI’s comparison page, still it would be nice to see some independent review of both companies. Especially on the financial prospects.
The information on trust is interesting. Does it mean that Alcor patients have a safer future in case the operation of Alcor is endangered?
What I found strange is that Alcor advertises itself as the only company using “perfusion technology” whatever it means as opposed to CI, whereas CI also insists on using the “best techniques currently available” and cites the same paper as Alcor. It is definitely unclear. The only clear dinstinction seems to be that Alcor uses full body vitrification if a premium is payed. Still, the price difference between 88K and 35K are staggering, even if the transportation/suspension costs are taken into account.
Thanks for the effort!
Of course I came to the above link and also to CI’s comparison page, still it would be nice to see some independent review of both companies. Especially on the financial prospects.
The information on trust is interesting. Does it mean that Alcor patients have a safer future in case the operation of Alcor is endangered?
What I found strange is that Alcor advertises itself as the only company using “perfusion technology” whatever it means as opposed to CI, whereas CI also insists on using the “best techniques currently available” and cites the same paper as Alcor. It is definitely unclear. The only clear dinstinction seems to be that Alcor uses full body vitrification if a premium is payed. Still, the price difference between 88K and 35K are staggering, even if the transportation/suspension costs are taken into account.